Acute Lymphoblastic Leukemia, Version 2.2015.

Published

Journal Article

Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org.

Full Text

Cited Authors

  • Alvarnas, JC; Brown, PA; Aoun, P; Ballen, KK; Barta, SK; Borate, U; Boyer, MW; Burke, PW; Cassaday, R; Castro, JE; Coccia, PF; Coutre, SE; Damon, LE; DeAngelo, DJ; Douer, D; Frankfurt, O; Greer, JP; Johnson, RA; Kantarjian, HM; Klisovic, RB; Kupfer, G; Litzow, M; Liu, A; Rao, AV; Shah, B; Uy, GL; Wang, ES; Zelenetz, AD; Gregory, K; Smith, C

Published Date

  • October 2015

Published In

Volume / Issue

  • 13 / 10

Start / End Page

  • 1240 - 1279

PubMed ID

  • 26483064

Pubmed Central ID

  • 26483064

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0153

Language

  • eng